Clinical Trials in Ars-Laquenexy, France
4 recruiting
Showing 1–6 of 6 trials
Recruiting
Phase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Cardiovascular DiseasesHypertensionDiabetes Mellitus, Type 2
Boehringer Ingelheim11,800 enrolled1152 locationsNCT07064473
Recruiting
Comparison of the Performance of the 2024 and 2017 McDonald Criteria for the Diagnosis of Multiple Sclerosis in Real Life
Multiple SclerosisEvent Suggestive of Multiple Sclerosis
Central Hospital, Nancy, France100 enrolled2 locationsNCT07492667
Recruiting
Natural History of Type 1 Interferonopathies: Insights From a European Cohort
Genetic DiseaseAutoimmune DiseasesNeurological Diseases or Conditions+1 more
Imagine Institute500 enrolled32 locationsNCT07040774
Recruiting
Phase 2
Carboplatin + Paclitaxel + Cetuximab (PCC) After Failure of Pembrolizumab +/- First-line Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Head and Neck Cancer
Centre Paul Strauss46 enrolled5 locationsNCT06725368
Recruiting
Phase 3
Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock
Cardiogenic Shock
Pr Bruno LEVY610 enrolled28 locationsNCT04020263
Recruiting
Phase 3
Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.
Cardiogenic Shock
Central Hospital, Nancy, France164 enrolled8 locationsNCT05879276